Playbook · Boston · Biotech and healthtech
LinkedIn playbook for Boston biotech and healthtech founders
A Kendall Square founder writes for scientists, pharma partners and investors at the same time, under rules that most LinkedIn advice ignores. This playbook shows what you can say, what you cannot, and how to stay visible anyway.
By Dr. Banpreet KaurUpdated 5 min read
- India ahead of Boston (US daylight time)
- 9.5 hrs
- FDA rule on promoting investigational drugs
- 21 CFR 312.7
The short answer
LinkedIn for Boston biotech and healthtech founders should explain the science, the team and the process in plain English, without presenting investigational products as safe or effective. Patient stories need HIPAA-safe handling, and public companies must respect Regulation FD and offering quiet periods. Specific, careful posts build partner and investor trust over months.
Who this playbook is for
This is for founders, CEOs and senior executives at Boston and Cambridge biotech, medtech, digital health and health IT companies, from seed-stage spinouts out of MIT and Harvard labs to public companies along the Kendall Square and Seaport corridors. It also fits physician-founders and scientific co-founders who would rather be in the lab than on LinkedIn.
Boston's life sciences cluster is one of the world's largest, and its density is both the advantage and the challenge. The pharma business development lead, the venture partner and the senior scientist you want to hire may all work within a few blocks of you. Each of them will look you up before taking a meeting. In a tighter funding market than the 2021 peak, a founder's public record of clear thinking does real work: partners who no longer take every coffee meeting still read LinkedIn.
The Boston audience and what it rewards
| Reader | What earns their trust | What loses them |
|---|---|---|
| Pharma business development and partnering leads | A clear mechanism, a defined patient population, honest data limits | Claims ahead of the evidence |
| Life sciences investors | Scientific rigor, capital discipline, team quality | Hype and vague "platform" language |
| Scientists and clinicians you want to hire | Hard problems, how decisions are made, credit to the team | Generic culture posts |
| Hospital and payer buyers (healthtech) | Workflow understanding, outcomes data, security | Consumer-style marketing |
| Patient advocacy groups | Respect, plain language, listening | Using patients as marketing props |
Boston readers are trained skeptics. A post that overstates a preclinical result will be noticed, and remembered.
The compliance line: FDA, HIPAA and securities rules
This is not legal or regulatory advice. Your regulatory affairs lead and counsel decide. A ghostwriter for this sector still needs to draft inside these lines:
- Investigational products. FDA rules at 21 CFR 312.7 bar sponsors, and anyone acting for them, from representing an investigational drug as safe or effective for the use under investigation, while still allowing scientific exchange. Devices have a parallel rule at 21 CFR 812.7. In practice: talk about the disease, the science, the trial design and the team; send anything about results to regulatory review; never write "safe", "effective", "cure" or "breakthrough" about a product that is not approved for that use.
- Patient information. If you work for or with a HIPAA-covered entity, HHS guidance says patient authorization is required for nearly all marketing uses of protected health information. Our default is composite or fully de-identified stories, with nothing taken from a record.
- Public companies and Regulation FD. The SEC's 2013 report on Netflix's CEO's Facebook post confirmed that Regulation FD applies to social media, and that companies may use those channels for material information only if investors have been told in advance. A CEO's post about trial readouts or partnerships can be material. Run it through investor relations.
- Quiet periods. Before and around an IPO or follow-on offering, counsel will usually restrict what executives say publicly. We pause or narrow posting when you tell us you are in one.
10 post angles for Boston life sciences founders
| Angle | Example hook (hypothetical) | Goal |
|---|---|---|
| The disease, not the drug | "Patients with [condition] wait [X] years, on average, for a diagnosis (cite the source). Here is why." | Partner and advocate audience |
| Mechanism in plain English | "Our approach explained to my mother, who was a nurse for 30 years." | Investor and recruit clarity |
| Trial design | "Why we picked a harder primary endpoint than the FDA required." | Scientific credibility |
| Failure and pivot | "The program we stopped last year taught us more than the one we kept." | Trust with investors |
| Team and lab culture | "Our best scientist joined after we lost her to another company. Twice." | Recruiting |
| Kendall Square reality | "Lab space is no longer the bottleneck in Cambridge. People are." | Local point of view |
| Capital discipline | "How we stretched a seed round to a value-inflecting result." | Investor audience |
| Healthtech workflow | "I shadowed a hospital pharmacist for a day. Our product was wrong about three things." | Hospital buyers |
| Partnering lessons | "What pharma BD actually asks in the first call." | Founder and partner audience |
| Patient voice (with consent) | "With her permission: what a caregiver told us about clinic visits." | Mission and empathy |
Voice notes for this market
- Precise and modest. Name the model, the endpoint and the sample size. "Encouraging early signal in mice" is honest; "promising cure" is not.
- Plain English for the general reader, one technical detail for the expert. That combination earns both audiences.
- Credit the team and the collaborators. Boston's science community is small and remembers who shared credit.
- No patient exploitation. Patient stories only with consent, de-identified, and never as product testimonials.
A 90-day plan
| Month | Focus | Output |
|---|---|---|
| 1 | Profile rewrite, interview, an agreed "say and do not say" list with regulatory and IR | Profile, 8 drafts, review workflow set |
| 2 | Disease, mechanism and team posts | 8 to 10 posts, comments on partners', investors' and advocates' posts |
| 3 | Process and point-of-view posts, conference follow-ups | 8 to 10 posts, partnering and recruiting conversations logged |
Align the calendar with the dates that matter for your audience: major partnering conferences, your own data readouts (posted only after IR clears them) and hiring pushes.
Common mistakes
- "Breakthrough" and "cure" for unapproved products. The fastest way to an uncomfortable regulatory conversation.
- Posting data before the press release. For public companies this can be a Reg FD problem.
- Patient photos or details without written authorization.
- Only posting at funding milestones. Investors and partners want to see consistent thinking, not occasional announcements.
Budget context
Boston companies usually compare a ghostwriting retainer with conference sponsorships and PR firm fees. Published 2026 ranges from The Digital Writing Firm put mid-tier specialists at about $1,500 to $3,500 a month and executive programs from $5,000 to $15,000 or more. Factor in regulatory and IR review time. Postlit does not publish prices; see our cost guide.
How Postlit works with Boston founders
We are a remote team in India with no Boston office. Our founder, Dr. Banpreet Kaur, trained as a doctor before becoming a content strategist, so clinical language does not need translating for us. India is 9.5 hours ahead of Boston during US daylight saving and 10.5 hours ahead after November 1, 2026.
- Send a short form by WhatsApp or email. A founder replies with a free written LinkedIn teardown, the three changes we would make first. A call follows only if it is a fit.
- Monthly 45-minute voice interview in your early morning, which is our evening.
- We write, your reviewers check, you approve. Drafts flag any investigational, patient or material-information risk for regulatory, legal or IR review.
- We engage and report. Comments on partners', investors' and scientists' posts during Eastern hours, and a monthly report.
Engagements are scoped on a call.
Want this running for you?
Get a free LinkedIn teardown. A founder reviews your profile and tells you what is costing you reach and what we would change first, whether or not you hire us.
Led by a Toptal Verified Expert in Marketing and a doctor turned content strategist.
Frequently asked questions
Can biotech founders post about investigational drugs on LinkedIn?
Carefully. FDA rules bar presenting an investigational drug or device as safe or effective for the use under study, though scientific exchange is allowed. Most founders post about the disease, the science, trial design and the team, and route anything on results through regulatory review first. Public companies should involve investor relations too.
Does Regulation FD apply to an executive's LinkedIn posts?
Yes, for public companies. The SEC's 2013 report on Netflix confirmed Regulation FD applies to social media, and companies can use those channels for material information only if investors were told in advance. Posts about trial data, partnerships or financials should be cleared by investor relations before publishing.
Why does personal branding matter for biotech and healthtech executives?
Partners, investors and senior scientists look you up before taking a meeting. A record of clear, careful posts about your science and team shortens the trust-building stage and makes cold outreach warmer. In a tighter funding market, that visibility matters more than sponsored conference presence.
Can healthtech founders share patient stories on LinkedIn?
Only with care. If you work with a HIPAA-covered entity, patient authorization is required for nearly all marketing uses of protected health information. The safe default is composite or fully de-identified stories, or stories shared with the patient's written consent, never details taken from a record.
How often should a biotech CEO post on LinkedIn?
Two posts a week is a sustainable rhythm that keeps regulatory and IR review manageable. Consistency matters more than volume. Plan around your real calendar, such as partnering conferences, hiring pushes and cleared data readouts, and pause during quiet periods if counsel advises it.